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1. Introduction  
Asthma has been a fascinating disease for millennia, while rhinitis has been recognized only 
for the last two centuries. Rhinitis has been defined so late in the medical practice because of 
other medical priorities, such as mortal infectious diseases or wounds. Due to a larger 
number of doctors in the community, better education, diminished impact of epidemics, 
better standard and increased lifetime, medical doctors have accomplished to observe and 
help their patients more than previously. A significant contribution to improving allergy 
management has been achieved through the ability of physicians to write and publish 
details about their work, exchange experiences, as well as test various hypotheses and 
perform various experiments. Despite an enormous increase in scientific work in all parts of 
the world, we still do not know what asthma and rhinitis are, but in the past few decades we 
have learned that those conditions are closely associated. 
Allergic rhinitis is one of the most common clinical presentations of allergy in human 
beings. It has been noticed that, during the 1990s, at the end of the past century, the 
prevalence of rhinitis doubled1. Allergic rhinitis is one of the 10 most common reasons for 
visiting general practitioners2. Allergic rhinitis is highly associated with doctor-diagnosed 
asthma. In an Italian study involving 18.647 subjects, a relative risk ratio (RRR) of 12.48 was 
obtained concerning the association between asthma and rhinitis3. Allergic rhinitis depends 
on the atopic status of the individual with an allergic reaction to a causative allergen, as well 
as on allergen exposure.  
Asthma is defined as ‘’a common chronic disorder of the airways that is complex and 
characterized by variable and recurring symptoms, airflow obstruction, bronchial 
hyperresponsiveness, and an underlying inflammation4.’ It is estimated that 30 million 
people in Europe have asthma, with the economic cost of asthma amounting to € 17 billion 
per year5. Among the asthmatic population, those who have allergic rhinitis represent 
different endotype of the asthma syndrome6. Distinct asthma phenotypes can be defined on 
the basis of the lung function, allergen sensitization, and symptoms characteristic of rhinitis 
and asthma. The asthma endotypes are defined on the basis of asthma phenotypes and the 
underlying pathophysiological mechanisms.  
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Patients with asthma and allergic rhinitis phenotypes have all asthma severity degrees, from 
intermittent through persistent mild, moderate and severe asthma. Some of them have just 
an early allergic reaction in bronchial mucosa, resulting in acute bronhchospasm, with 
recurrent wheezing, but some have a late asthmatic response. Allergic asthma and rhinitis 
usually respond well to inhaled corticosteroids. They are usually not dangerous in the case 
of severe asthma attacks, unless the patients show risk behavior. Such risks include: non-
compliance with the asthma treatment, exposure to extreme (atmospheric or toxic) 
conditions, and/or severe respiratory infections. They may be greatly modified depending 
on whether the patients are active or passive smokers. When an ill person is exposed to 
continuous toxic gases by his/her own will, such as smoking, the immune response in the 
airways alters. Acute exposure to cigarette smoke is associated with NF-B activation and 
synthesis of IL-8 in the alveolar macrophages. After being translocated into the nucleus, the 
activated NF-B binds with the DNA and regulates the expression of numerous genes 
involved in the inflammatory process7. The inflammatory cells are distributed unevenly 
throughout the bronchial tree, both large and small airways, and can be found both in 
asymptomatic smokers and in patients with chronic obstructive pulmonary diseases 
(COPD), whose main disease risk factor is smoking8. The only difference between the 
asymptomatic smokers and patients with a type of COPD was quantitative - the smokers 
with a COPD had a greater number of inflammatory cells, as shown in our own research9. 
The immunological changes in the airways caused by smoking enhance the functional 
derangement of the airways. Smoking in adolescence reduces the lung function growth rate, 
so that the expected value of forced expiratory volume in the first second (FEV1)10 is not 
attained. If adolescents gain a permanent habit of smoking, their decline in FEV1 starts much 
earlier than in non-smokers11. The pulmonary function is a function of age. This means that 
after birth the pulmonary function continues to evolve and grow, reaching its maximum in 
adolescence, followed by a plateau until the late twenties. Persons over 30 have a permanent 
annual physiological loss of lung volume and flow rate, 20-30 ml FEV1 per year. Smokers 
have a greater annual decline in FEV1 than non-smokers12 13, 60 ml per year14 on the average. 
In adolescents who smoke, the loss begins earlier than in non-smokers, significantly 
shortening the plateau of constant lung function in adolescence, and the process is even 
faster in the female population15, which is more vulnerable to cigarette smoke. A higher 
prevalence of asthma (OR 1.83) and rhinitis (OR 1.61) has been found in adolescent smokers 
than in non-smokers. It has been found that people with 1-10 pack years have an odds ratio 
(OR) of 1:47 for developing more severe types of asthma compared to non-smokers with 
allergic rhinitis, while those with over 20 pack years have a risk OR of 5:59, also compared 
to allergic non-smokers. Pack years represent the index of total exposure to tobacco smoke, 
or the overall smoking history. Pack years are important for the assessment of the risk of 
developing a disease. It is believed that the quantification of over 10 pack years significantly 
increases the risk of occurrence of a COPD, while the quantification of over 20 pack years 
represents a high risk of developing lung cancer and heart attack. Each medical document of 
a person who smokes, not just pulmonary or cardiac where it is essential, but particularly 
general practice documents, should contain the data on pack years. Pack years are 
calculated by using the following formula: 
Number of cigarettes per day
Pack years  X years of smoking
20
  
An average person is not fully aware of the entire problem of smoking and its impact on 
human health. Smoking is considered to be the biggest risk factor associated with the global 
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burden of disease in developed countries and amounts to 12.2%, expressed in disability 
adjusted life years (DALY), according to the World Health Organization (WHO). Every 8 
seconds someone in the world dies from smoking related diseases16. Smoking is a risk factor 
associated with six of the eight leading causes of death worldwide17. Smoking affects the 
occurrence of disease, its outcome, and in case the outcome is not death, the success of 
treatment also depends on whether the person is an active or former smoker. The answer to 
how this is possible lies in the chemical composition of tobacco smoke. Cigarette smoke has 
over 4000 chemical substances, 3000 respiratory irritants and about 1000 other noxious 
chemical substances. The International Agency for Research on Cancer has included more 
than 60 substances in the group of carcinogens18. To improve the effect of smoking on the 
palate (pH changes from acidic to alkaline and increases potential addiction), tobacco leaves 
are combined with additives. In the United States of America (USA), these additives are 
regulated in the form of a list of 599 substances19. Tobacco smoke is full of free oxygen 
radicals (up to the extreme number of 1017) and each radical is an unstable molecule. These 
radicals damage the tissue by their unpredictable and random binding with any other 
molecules in the vicinity, thus creating further unstable molecules, new radicals, which 
cause further tissue damage, up to the DNA level. Oxidants and free radicals cause 
sequestration and accumulation of neutrophils in the pulmonary microcirculation, as well as 
accumulation of macrophages in the respiratory bronchioli, with macrophages being a 
potential reservoir of new oxidants20.  
Another important fact is that there are no less harmful cigarettes with low tar content 
('light') or a safe level of smoking. European legislation prescribes limitation of the cigarette 
tar content to 10 mg, nicotine to 1 mg and carbon monoxide to 10 mg per cigarette, which 
has been incorporated in the Regulation on Health Safety of General Use Items since 
January 1, 2005 (Official Gazette 42/2004) in the Republic of Croatia. As far as the so-called 
light cigarettes are concerned, there is a misconception that they contain smaller quantities 
of harmful substances. Light cigarettes are made in the way that nicotine is overheated and 
carbon dioxide (CO2) is blown into it until it assumes the form of expanding foam used to 
fill the same cigarette paper as ordinary tobacco. Also, light cigarettes have vent holes in the 
filters to assure that smoke is diluted with air during inhalation. Therefore, smokers of this 
type of cigarettes inhale more deeply on the average and actually receive the same amount 
of tar and nicotine. 
There is yet another important fact that the general public is usually not aware of, and that is 
the influence of passive smoking on health. Passive smoking is defined as involuntary 
inhalation of tobacco smoke. Cigarette smoke coming from a burning cigarette tip is called 
second-hand smoke (SHS). The smoke remaining after putting the cigarette out is called 
environmental tobacco smoke (ETS). Cigarette smoke remains in the room air for the next 8 
hours! 21 Tobacco smoke exhaled by a smoker may be the worst of them all, because the 
substances in cigarette smoke change after getting in contact with human tissue enzymes. 
Environmental tobacco smoke (ETS) is a mixture of second-hand smoke and smoke exhaled 
from the lungs of smokers. Scientific evidence on passive smoking have provided non-
smokers with strong arguments in their demands to breathe clean air and prohibit smoking 
in indoor areas, which is now supported by legislation in most developed countries. 
It is believed that passive smoking causes 10% of disease mortality in the world, in children 
mostly due to lower respiratory tract infections (5,939 million) and asthma (651,000), and in 
adults due to ischemic heart disease (2,836 million) and also asthma (1,246 million), 
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according to the 2004 data published in the Lancet based on the analysis of results from 192 
countries worldwide22. It is believed that persons exposed to second-hand smoke have a 
higher production of immunoglobulin E (IgE), total and specific IgE to certain allergens23. 
Passive smoking has been proved to increase the risk of asthma in children. An 
epidemiological study of 53,879 children showed that passive smoking, either prenatal or 
postnatal, significantly increases the probability of asthma in children, as well as the 
occurrence of respiratory problems such as night time cough and wheezing24. Another large 
nationwide study of 102,000 children in the United States proved the connection between 
tobacco smoke exposure in children in their homes and prevalence of asthma, with a 
significance level of p = 002625. The quality of atmospheric air or socioeconomic status of the 
family did not affect this correlation between asthma and household smoking. Since the 
prevalence of asthma increased three times in the past few decades, there are hypotheses 
that this increase is at least partly caused by the observed major increase in cigarette 
consumption in the past century26. That increase in cigarette consumption further increases 
the exposure to second-hand smoke, especially in children, thus also increasing the 
incidence of childhood asthma. It has been shown that the proportion of exhaled nitric oxide 
(FENO), which is used as a biomarker of airway inflammation in asthma, is associated with 
the exposure of children to environmental tobacco smoke at the age of 427. Similar data 
found with regards to the adult population confirms that exposure to tobacco smoke in the 
environment increases the occurrence of asthma and its exacerbations28. 
These data imply that exposure to toxic ingredients of cigarette smoke is highly associated 
with allergic rhinitis and/or asthma, as well as to the probability of developing asthma, 
especially more severe exacerbations. In this study, we were interested to find out whether 
smoking poses a risk on the presentation of allergic rhinitis and/or asthma, and on clinical 
variants of these respiratory allergy diseases in patients with diagnosed allergic rhinitis and 
asthma phenotypes.  
2. Methods 
The pulmonologists from the Outpatient Department of the Zagreb University Hospital 
Center, Jordanovac Lung Disease Clinic, located in the moderate continental climate area of 
Central and Eastern Europe (Zagreb, Croatia) recruited 120 adult asthma patients in 
consecutive order for purposes of a study carried out in the period from 2006 to 2009 in 
which 78 healthy persons constituted the control group, in total 198 subjects. They were 
considered healthy if they had no previous respiratory diseases, and if they answered 
negative to all questions from the Screening ECRHS II Questionnaire. The European 
Community Respiratory Health Survey (ECRHS) was part of the European Commission 
Quality of Life Programme and a nine-year prospective collaborative study carried out in 14 
European countries, which collected data from more than 10 000 young adults29.  
All patients had had doctor-diagnosed asthma for longer than 6 months, based on a detailed 
interview. The symptoms that were considered asthmatic included: chronic cough, 
expectoration, wheezing, shortness of breath, chest tightness, exercise impairment, or night 
awakening. The age at asthma appearance, the number of asthma exacerbations and their 
severity and frequency were available; and the daily and night symptoms, exercise 
impairment, and dosing of rescue medication (short-acting 2 agonists) were obtained. The 
data on sports and smoking habits were also collected. The severity of asthma was classified 
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according to the Global Initiative for Asthma (GINA) into intermittent, mild persistent, 
moderate or severe persistent asthma30. The level of asthma control was assessed by 
applying the Asthma Control Test (ACT)31. The symptoms that were considered rhinitic 
included: sneezing, watery secretion, nasal blockage, and nasal itching32. The patients with 
allergic rhinitis or nasal polyps had ENT specialist-established diagnosis.  
After examination, all patients performed spirometry and had to fill out a standardized 
questionnaire for asthmatic patients (ECRHS). Spirometry was performed at least three 
times from normal breathing followed by slow inhalation to a maximum, on a MasterLab 
Pro, version 4.3, an apparatus with a pneumotachograph. The best attempt was selected and 
forced expiratory volume in the first second (FEV1) recorded according to the standard 
spirometric procedure (ATS/ERS)33 and then compared with the referent values according 
to the European Community for Coal and Steel34. The existence of an obstructive ventilatory 
disorder was considered if FEV1 was less than 80% of the predicted value, and the 
FEV1/FVC ratio under 0.7. The bronchodilator reversibility was tested with 400 g of the 
short acting 2-agonist (salbutamol) and considered positive if the FEV1 increased by 12% 
and/or 200 ml after 15-30 minutes35,36.  
The skin prick tests (SPT) were performed on the forearm, with 15 aeroallergens 
manufactured by Stalallergen, France (Dermatophagoides pteronyssinus, Dermatophagoides 
farinae, cat dander, dog dander, moulds (Aspergillus fumigatus, Alternaria alternata, 
Cladosporium herbarum, Candida albicans), Latex, hazel tree pollen (Corylus avellana), birch 
pollen (Betulla verrucosa), grass pollen mixture (Phleum pratense, Lolium perenne, Dactylis 
glomerata, Festuca elatior, Poa pratensis), rye pollen (Secale cereale), short ragweed pollen 
(Ambrosia elatior), mugworth pollen (Artemisia vulgaris). Negative (saline solution) and 
positive (histamine 1 mg/ml) controls were used. After 15 minutes, the diameter was 
measured in millimeters (mm), the long axis (D) and its perpendicular (d). A particular skin 
prick test was considered positive when the mean wheal size was greater than 3 mm in 
relation to the negative control (D+d)/2337. The patients had not taken any 
antihistamines, anti-depressives or any other therapy which could influence the results of 
the SPT for at least a week prior to the testing. Descriptive statistics, correlation, t-tests and 
chi square tests were used for data analysis by means of standard statistical programs.  
3. Results  
From among the 198 subjects involved in this study, 120 patients had the asthmatic 
syndrome, 104 had allergic rhinitis and asthma, while 16 had only allergic asthma (Table 1). 
The duration of allergic rhinitis (AR) was significantly longer than the duration of asthma, 
p<0.001 (Table 2). As far as gender is concerned, the sample of patients with allergic rhinitis 
and asthma consisted of significantly more female subjects (Table 3). 
 
 n (%) 
asthma only 16 (8.1) 
asthma with AR 104 (52.5) 
healthy 78 (39.4) 
total 198 (100.0) 
Table 1. Share of participants with asthma, allergic rhinitis and healthy participants 
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 Mean (SD) Median (IQR) Min Max 
Shapiro-
Wilk Test 
Age at first onset (in years)        
asthma 32 (17.9) 30 (17-44.5) 1 70 P=0.264 
allergic rhinitis 28 (16.2) 30 (14-40) 1 64 P=0.122 
Duration of illness (in years)    
asthma 10 (10.1) 5 (2-19) 0 32 P<0.001 
allergic rhinitis 13 (10,5) 10 (3-21) 1 40 P=0.005 
Abbreviation: Mean = arithmetic mean; SD = standard deviation; IQR = interquartile range; Shapiro 
Wilk Test for normality of distribution 
Table 2. Asthma and allergic rhinitis descriptive parameters 
 
 Male Female 
P 
 n (%) n (%) 
Diagnosis     0.368 
asthma only 6 (17.6) 9 (11.0)  
asthma with AR 28 (82.4) 73 (89.0)  
total 34 (100.0) 82 (100.0)  
Abbreviations: P = Fisher's Exact Test; level of statistical significance, or probability of type I (alpha) 
Table 3. Prevalence of asthma and allergic rhinitis by gender 
4. Predictors of AR and asthma 
4.1 Smoking and non-smoking as Predictors of AR and asthma  
 
 
Group 
total 
OR (95%CI) patients healthy 
n (%) n (%) n (%) 
never smoked 14 (31) 31 (69) 45 (100) 1 
smoked 59 (56) 47 (44) 106 (100) 2.8 (1.3-5.8) 
Abbreviations: OR = odds ratio; 95%CI = 95% confidence interval for odds ratio 
Fisher Exact Test, P = 0.07 
Table 4. Prevalence of patients by their smoking history; base: whole sample (n =151) 
Ever-smoking proved to be a statistically significant predictor of developing asthma or 
allergic rhinitis. The prevalence of respondents with asthma or allergic rhinitis among those 
who had smoked at least once in their life (or still smoke) was significantly higher, 59/106 
(56%), than among the respondents who had never smoked 14/45 (31%). The odds for being 
diagnosed with allergic rhinitis and asthma was 2.8 times and statistically significantly 
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higher among those who had smoked or still smoke than the odds for the illness among those 
who had never smoked (binary logistic regression; exposed to smoke B coefficient = 1.02; 
standard error = 0.38; odds ratio = 2.48 95% CI = 1.3-5.8). The proportion of smokers, former or 
current, in the whole sample of asthmatic or healthy persons was more than one half (53.5%).  
In the group of active smokers, the smoking history amounted to 24.187.49 pack years, 
while in the group of former smokers the smoking history amounted to 17.534.62 pack 
years.  
 
 
Group  
total 
LR; df; P asthma only 
allergic rhinitis 
and asthma 
healthy 
n (%) n (%) n (%) n (%) 
never smoked 2 (5) 8 (20) 31 (76) 41 (100) 7.704; 2; 0.02 
smoked 8 (9) 38 (41) 47 (51) 93 (100)  
Abbreviations: OR = odds ratio; 95%CI = 95% confidence interval for odds ratio;  
LR = likelihood ratio, P = level of statistical significance, or probability of type I (alpha) 
Table 5. Prevalence of patients by their smoking history; base: whole sample (n =134) 
The patients and healthy respondents differed statistically significantly in terms of whether 
they had ever smoked in life (likelihood ratio = 7.704, P = 0.02). Among the patients who 
had smoked or smoke, 8/93 (9%) had asthma, compared to 2/41 (5%) of those who had 
never smoked. Also, 38/93 (41%) of those who had smoked had asthma and allergic rhinitis, 
compared to 8/41 (20%) who had never smoked.  
 
 
Diagnosis 
total 
OR (95%CI) 
allergic rhinitis 
and asthma 
no respiratory 
disease 
N (%) n (%) n (%) 
never smoked 8 (21) 31 (79) 39 (100) 1 
smoked 41 (47) 47 (53) 88 (100) 3.4 (1.4-8.2) 
Abbreviations: OR = odds ratio; 95%CI = 95% confidence interval for odds ratio 
Fisher Exact Test, P = 0.06 
Table 6. Prevalence of allergic rhinitis and asthma by their smoking history (at least once or 
never); base: allergic rhinitis + asthma and healthy (n=127) 
Ever-smoking proved to be a statistically significant predictor of allergic rhinitis and 
asthma. The prevalence of allergic rhinitis and asthma among the respondents who had 
smoked at least once in their life (or still smoke) was significantly higher, 41/88 (47%), than 
among the respondents who had never smoked, 8/39 (21%). The odds for being diagnosed 
with allergic rhinitis and asthma was 3.4 times and statistically significantly higher among 
those who had smoked or still smoke than the odds for developing these illnesses among 
those who had never smoked (binary logistic regression; exposed to smoke B coefficient = 
1.22; standard error = 0.45; odds ratio = 3.4; 95% CI = 1.4-8.2).  
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Fig. 1. Prevalence of allergic rhinitis and asthma by smoking history (at least once or never); 
base: whole sample, (n=127) 
 
 
Fig. 2. Prevalence of allergic rhinitis and asthma by current non-smokers, former smokers, 
and non-smokers; base: whole sample, (n=103)  
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Current smoking proved to be a statistically significant predictor of allergic rhinitis and 
asthma in comparison to non-smoking. Current smoking accounted for approximately 7.3% 
of the variants of allergic rhinitis and asthma (Nagelkerke R squared = 0.073). Current 
smokers had a 3.1 (310%) time greater chance of developing asthma and allergic rhinitis. 
13/29 (45%) current smokers had asthma and allergic rhinitis, compared to 7/34 (21%) 
people who had never smoked (binary logistic regression, current smokers B coefficient = 
1.14; standard error = 0.55; odds ratio = 3.1, 95% CI = 1.0 to 9.5). 
4.2 Daily exposure to tobacco smoke and current smoking as predictors of AR and 
asthma 
 
 
Diagnosis 
total 
OR (95%CI) 
allergic rhinitis 
and asthma 
no respiratory 
disease 
n (%) n (%) n (%) 
non-smokers        
not exposed to smoke 6 (14) 38 (86) 44 (100) 1 
exposed to smoke 10 (33) 20 (67) 30 (100) 3.2 (1.0-10.0) 
smokers 13 (45) 16 (55) 29 (100) 5.2 (1.7-15.9) 
Abbreviations: OR = odds ratio; 95%CI = 95% confidence interval for odds ratio 
Likelihood ratio=9.3; df=2; P=0.01; contingency coefficient = 0.28 
Table 7 Prevalence of allergic rhinitis and asthma by current non-smokers’ daily exposure to 
tobacco smoke and current smoking; base: whole sample, (n=103) 
Both daily exposure to tobacco smoke among current non-smokers and current smoking 
proved to be statistically significant predictors of allergic rhinitis and asthma. The 
prevalence of allergic rhinitis and asthma among the current non-smokers who had been 
daily exposed to tobacco smoke during the period of 12 months prior to the study, was 
10/30 (33%) in comparison to the current non-smokers who had not been daily exposed to 
tobacco smoke, 6/44 (14%). The odds for being diagnosed with allergic rhinitis and asthma 
were 3.2 times and statistically significantly higher among the current non-smokers who 
had been daily exposed to tobacco smoke than the odds for developing these illnesses 
among the current non-smokers who had not been daily exposed to tobacco smoke (binary 
logistic regression; exposed to smoke B coefficient = 1.25; standard error = 0.59; odds ratio = 
3.2; 95% CI = 1.0-10.0).  
The prevalence of allergic rhinitis and asthma among the current smokers, 13/29 (45%), was 
about three times higher than among those who had not been daily exposed to tobacco 
smoke, 6/44 (14%). The odds for developing these illnesses were 5.2 times and statistically 
significantly higher in the case of smokers (binary logistic regression; smokers B coefficient 
= 1.64; standard error = 0.58; odds ratio = 5.2; 95% CI = 1.7-15.9). 
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Fig. 3. Prevalence of allergic rhinitis and asthma by current non-smokers’ daily exposure to 
tobacco smoke and current smoking; base: whole sample, (n=97) 
4.3 Prevalence of patients who quit or reduced smoking  
The healthy respondents and those with allergic rhinitis and asthma did not differ 
significantly with regard to quitting or reducing smoking (Fisher Exact Test, P = 0.249). 
Among those with allergic rhinitis and asthma however, the difference between those who 
quit or reduced smoking and those who didn’t was statistically significant (goodness of fit 
Hi square = 20.83; df = 1; P < 0.01), 88% quit or reduced smoking, while 12% of them still 
smoke as before.  
 
 
Diagnosis  
allergic rhinitis 
and asthma 
no respiratory 
disease 
P 
n (%) n (%)  
didn’t reduce 4 (12) 11 (23) 0.249 
reduced 29 (88) 36 (77)  
TOTAL 33 (100) 47 (100)  
Abbreviations: OR = odds ratio; 95%CI = 95% confidence interval for odds ratio 
P = Fisher Exact Test; level of statistical significance, or probability of type I (alpha) 
Table 8. Prevalence of those who quit or reduced smoking by illness (allergic rhinitis and 
asthma); base: whole sample (n=70)  
www.intechopen.com
Clinical Variants of Allergic Rhinitis  
and Asthma Phenotypes in Patients with or Without a Smoking History 
 
71 
5. Allergy diagnostic tests (skin prick tests) 
The skin prick tests in the healthy control group were negative in the case of all tested 
subjects. The patients with allergic rhinitis and asthma endotypes associated with smoking 
were significantly more sensitized to perennial allergens, mostly to Dermatophagoides 
pteronyssinus (54% of patients in the ever-smoking group and 39% in the non-smoking 
group). In the non-smoking group of patients with allergic rhinitis and asthma, greater 
sensitization was recorded to seasonal allergens, most often to grass pollen (31% of patients 
in the ever-smoking group and 42% in the non-smoking group).  
 
 X SD Min. Max. SE 
Histamine ever-smokers 6.25 1.38 3 11 0.21 
Histamine non-smokers 7.40 1.57 4 12 0.27 
Der p ever-smokers 5.69 1.75 3 9 0.19 
Der p non-smokers 5.87 1.83 3 14 0.21 
Fel d ever-smokers 5.71 1.54 4 13 0.17 
Fel d non-smokers 5.92 1.67 3 13 0.16 
Alt a ever-smokers 4.91 1.22 3 8 0.12 
Alt a non-smokers 5.11 1.34 3 9 0.14 
Bet v ever-smokers 7.63 1.68 4 22 0.31 
Bet v non-smokers 8.14 1.82 5 25 0.29 
Phl p ever-smokers 6.88 1.91 5 18 0.24 
Phl p e non-smokers 7.49 1.82 4 27 0.28 
Amb e ever-smokers 7.36 1.65 5 19 0.31 
Amb e non-smokers 8.10 1.78 5 32 0.34 
Abbreviation: X = arithmetic mean; SD = standard deviation: Min.= minimal value; Max.= maximal 
value; SE=standard error; mm=millimeters; Der p=Dermatophagoides pteronyssinus; Fel d=Felis 
domestica; Alt a= Alternaria alternata, Bet v= Betula verrucosa; Phl p= Phleum pratense; Amb e= 
Ambrosia elatior. 
Table 9. Results of skin prick tests to common inhalation allergens in allergic rhinitis and 
asthma phenotypes patients with or without a smoking history, reaction by wheal size in 
mm (positive control: histamine (1 mg/ml), negative control: saline solution). 
The wheal reaction to common inhalation allergens (size in mm) in allergic rhinitis and 
asthma phenotypes patients showed a bigger diameter in patients without a smoking 
history than in the group of allergic ever-smoking patients (Table 17). The skin wheal 
reaction to pollen allergens was greater than the reaction to perennial allergens in the case of 
all patients.  
6. Clinical symptom variants in allergic rhinitis and asthma  
All subjects in the group of subjects with allergic rhinitis and asthma phenotypes had a few 
symptoms of their disease, at least three, but most subjects had more than five symptoms. 
The distribution of their symptoms differed whether they were current or former smokers or 
lifetime non-smokers. Table 18 shows less histamine-mediated symptoms of allergic rhinitis, 
such as sneezing or runny nose, in the medical history of non-smoking patients than in the 
group of smokers, however more blocked nose. 
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With a smoking history 
(ever-smokers) 
n=59 
Without a smoking history 
(non-smokers) 
 n=45 
Sneezing 28 (48%) 27 (61%) 
Runny nose 25 (43%) 23 (52%) 
Blocked nose 42 (72%) 24 (54%) 
Itchy nose 12 (21%) 14 (32%) 
Itchy eyes (conjunctivitis) 21 (36%) 12 (27%) 
Table 10. Clinical presentation of rhinitic symptoms in patients with allergic rhinitis and 
asthma phenotypes with or without a smoking history 
 
 
With a smoking history 
(ever-smokers) 
n=68 
Without a smoking history  
(non-smokers) 
 n=52 
Cough 58 (85%) 32 (61%) 
Expectoration 52 (76%) 15 (29%) 
Wheezing 27 (39%) 30 (57%) 
Chest tightness 13 (19%) 21 (41%) 
Shortness of breath 22 (32%) 21 (40%) 
Exercise impairment 17 (25%) 17 (33%) 
Night awakening 14 (21%) 19 (37%) 
Asthma exacerbation (moderate/severe) 21 (31%) 14 (26%) 
ACT (mean value out of exacerbation) 16 20 
Abbreviations: ACT= Asthma Control Test 
Table 11. Clinical presentation of asthmatic symptoms in patients with allergic rhinitis and 
asthma phenotypes with or without a smoking history 
The respondents with the ever-smoking habit showed less chest tightness, night awakening 
and exercise impairment, compared to the non-smoking group, but more moderate or 
severe asthma exacerbations, with lower asthma control.  
 
 With a smoking history  
(ever-smokers) 
n=68 
Without a smoking history  
(non-smokers) 
 n=52 
GINA I 3 (04%) 2 (05%) 
GINA II 18 (26%) 20 (39%) 
GINA III 41 (61%) 26 (49%) 
GINA IV 6 (09%) 4 (07%) 
Abbreviations: GINA= Global Initiative for Asthma 
Table 12. Distribution of diagnosed patients with allergic rhinitis and asthma phenotypes 
according to the GINA classification, with or without a smoking history 
7. Lung fnction (FEV1) 
The distribution of forced expiratory volume in the first second (FEV1) level did not deviate 
significantly from the normal distribution among all patients (Shapiro Wilk = 0.994, P = 
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0.698), among those with asthma only (Shapiro Wilk = 0.962, P = 0.698) or among those with 
asthma and allergic rhinitis (Shapiro Wilk = 0.982, P = 0.490). 
 
 Mean (SD) Median (IQR) Min Max 
Shapiro-
Wilk Test 
Whole sample 78.7 (19.87) 79.4 (66.3-93.3) 30 140 P = 0.698 
Asthma only 77.1 (21.11) 77.2 (62.9-96.7) 39 106 P = 0.816 
Asthma and allergic rhinitis 79.9 (21.56) 80.8 (67.3-95.8) 30 124 P = 0.490 
Abbreviation: Mean = arithmetic mean; SD = standard deviation; IQR = interquartile range; 
Shapiro Wilk Test for normality of distribution 
Table 13. FEV1 (% of the reference value) 
 
 FEV1 P 
 Mean SD 
never smoked 15.22 4.97 <0.05 
smoked 8.62 5.14  
Abbreviation: Mean = arithmetic mean; SD = standard deviation 
Table 14. Difference in the FEV1 average increase (%) after the bronchodilator test with 
salbutamol by current and ever-smokers, base: only ill (n=47) 
The bronchodilator response in the smoking group was statistically significantly lower than 
in the non-smoking group.  
Considering the skin sensitization established on the basis of skin prick tests there were 
more patients sensitized to perennial allergens in the smoking group (active and former 
smokers), most to Dermatophagoides pteronyssinus (58%), followed by those sensitized to 
ragweed pollen (Ambrosia elatior) (34%). In the non-smoking group of patients with allergic 
asthma, seasonal allergies were more recorded, mostly to grass pollen (42%), while ragweed 
pollen and tree pollen were similarly distributed (32% and 31%).  
The exacerbation rate in both groups did not differ significantly, which may be due to the 
low number of study groups. Only 4/120 (3.3%) patients were hospitalized due to asthma 
exacerbations during the observation period. 11/120 (9.2%) ever-smoking patients were 
hospitalized for asthma exacerbations, some of them even several times. Intensive care 
treatment was needed in the case of 2/120 (1.7%) patients, however no intubation or 
mechanical ventilation was necessary. 
8. Discussion  
Allergic rhinitis and asthma are frequent diseases posing a heavy burden for the society. 
Allergic rhinitis and asthma presented together are considered to be different asthma 
phenotype and endotype. The allergic reaction is modified depending on whether the 
patients are active or passive smokers. A large proportion of patients with allergic rhinitis 
and asthma are smokers. Our hypothesis was that there were differences in the clinical 
presentation of allergic rhinitis and asthma phenotypes due to exposure to tobacco smoke.  
In the investigated group of patients with allergic asthma, those who also had allergic 
rhinitis made up a significantly greater number (104/120) compared to the asthmatics 
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without allergic rhinitis. The prevalence of allergic rhinitis in asthmatics in the case of our 
subjects was 86.7% (Table 1), involving significantly more female subjects (Table 3). Even in 
children from 6-12 years of age, it was found that 89.7% had moderate to severe rhinitis, 
which means that they have troublesome sleeping, problems with concentration and 
diminished learning results38.  
From the total sample of 198 subjects, both in the case of asthmatic and healthy subjects, 
there were more former or current smokers (106/198) than persons who had never smoked. 
The proportion of ever-smokers investigated in this study (53.5%) is greater than the 
proportion of ever-smokers in the general population, according to the epidemiological 
survey conducted on adults39 and medical students in Croatia40. The mentioned surveys 
showed there were 27.4% regular daily smokers over 18, of which 34% men and 22% 
women.  
Active smokers had a slightly higher number of pack years than former smokers, however 
not significantly higher. In the group of active smokers, the number of pack years amounted 
to 24.187.49, while in the group of former smokers the number of pack years amounted to 
17.534.62. These data show that most smokers smoke for more than a decade or two before 
starting to consider quitting smoking and before they succeed to do it. Most literature data 
based on various studies confirm our results. Quitting smoking is a process with several 
phases preceding the change in behavior, which has been known for a longer period41. As 
smoking produces nicotine addiction, it is not easy to quit smoking due to the abstinence 
syndrome. Besides a strong motive, some smokers might need a nicotine replacement 
therapy with pharmacological agents, vareniclin or bupropion, which increases the rate of 
successful quitters42.  
The odds for being diagnosed with allergic rhinitis and asthma in our study was 2.8 times 
and statistically significantly higher among those who had smoked or still smoke than the 
odds for developing these illnesses among those who had never smoked (Table 4). The data 
from other authors also show that smokers are more likely to develop asthma than non-
smokers, although smoking is not believed to cause asthma43. Tobacco smoking causes 
increased bronchial hyperreactivity44. After quitting smoking, bronchial hyperreactivity in 
asthma patients decreases in comparison to the asthma patients who continue to smoke45.  
Among the patients who had smoked, 9% had asthma, compared to 5% of those who had 
never smoked. Also, 41% of those who had smoked had asthma and allergic rhinitis, 
compared to 20% of those who had never smoked. These results are statistically significant 
(p=0.02), with the likelihood ratio of 7.7 for developing allergic asthma and rhinitis if 
smoking (Table 5).  
Ever-smoking proved to be a statistically significant predictor of allergic rhinitis and 
asthma. The prevalence of allergic rhinitis and asthma among the respondents who had 
smoked at least once in their life (or still smoke) was significantly higher, 47%, than among 
the respondents who had never smoked, 21% (Table 6) 
Daily exposure to tobacco smoke among current non-smokers and current smokers proved 
to be a statistically significant predictor of allergic rhinitis and asthma. There were 45% of 
current smokers in our group with allergic rhinitis and asthma, more than in Northern 
America where there were 25-35%46. The investigated current smokers, in comparison to the 
investigated former smokers, had a 3.1 time greater chance of developing asthma and 
allergic rhinitis (Figure 2). The non-smokers who had been exposed to tobacco smoke 
during the last 12 months prior to the study, had a 3.2 time greater chance of developing 
asthma and allergic rhinitis (odds ratio = 3.2; 95% CI = 1,0-10,0) in comparison to the non-
exposed non-smokers. Also in comparison to the non-exposed non-smokers, the current 
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smokers, daily exposed to cigarette smoke, had a 5.2 time greater chance of developing 
asthma and allergic rhinitis (odds ratio = 5.2; 95% CI = 1.7-15.9) (Table 7). Daily exposure to 
tobacco smoke among the former smokers did not prove to be a statistically significant 
predictor of allergic rhinitis and asthma (odds ratio = 0.9; 95% CI = 0.9-11.2). 
The healthy respondents and those with allergic rhinitis and asthma did not differ 
significantly with regards to reducing the number of cigarettes. Most subjects tried to reduce 
smoking (77% vs. 88%) (Table 8). These results are in concordance with the known fact that 
more than 70% of smokers want to quit smoking47.  
The bronchodilator response in the smoking group was statistically significantly lower than 
in the non-smoking group, p<0.05. (8.62%5.14 vs.15.22%4.97, p<0.01) (Table 14). As it is 
known that smokers have higher levels of total immunoglobulin E (IgE)48 and a greater 
degree of infiltration of inflammatory cells, especially eosinophils49, in comparison to non-
smokers, it is most likely that inflammatory processes will lead to airways remodeling and 
fixed bronchial obstruction, with lower reversibility. 
As far as skin sensitization established on the basis of skin prick tests is concerned, a greater 
number of patients from the smoking group (active and former smokers) were sensitized to 
perennial allergens, while the non-smoking patients with allergic asthma and rhinitis were 
more sensitized to seasonal allergens. The ever-smoking patients were most usually 
sensitized to Dermatophagoides pteronyssinus (54%), while the non-smoking allergic 
patients were more often sensitized to grass pollen (42%). The wheal reaction of the skin to 
common inhalation allergens in allergic rhinitis and asthma endotypes showed a bigger 
diameter in patients without a smoking history than in the group of allergic patients who 
had smoked at least once in their life (Table 9). It seems that smoking diminishes the 
histamine reaction, which is contrary to most literature data about the increased release of 
proinflammatory mediators50.  
The distribution of the patients’ symptoms differed whether they were current or former 
smokers or if they were lifetime non-smokers. The allergic rhinitis phenotypes included the 
clinical variants with nasal blockage as the most frequent symptoms in the smoking group. 
On the contrary, histamine mediated symptoms of allergic rhinitis, such as sneezing or 
runny nose, were less expressed in the group of patients with smoking in their medical 
history than in the group of non-smoking patients (Table 10).  
These results could be influenced by different sensitization in the smoking (more to 
perennial allergens) and the non-smoking group (more to seasonal allergens). Another 
study revealed more nasal blockage in the group of patients with persistent allergic rhinitis, 
mainly due to house dust mite allergy51.  
The asthma phenotypes included the clinical variants of more expressed chronic cough (85% 
vs. 61%) and/or expectoration (76% vs. 29%) in the investigated group of smokers than in 
the group of non-smokers (Table 11). The asthma phenotypes could be marked by: a) 
baseline pulmonary function measures: b) specific allergen sensitization by SPT; c) self-
reported allergies; d) symptoms characteristic of rhinitis, and e) symptoms characteristic of 
asthma52. The asthma phenotypes were identified as important for the genetic study of 
asthma and because they might have an impact on the response to asthma therapy53.  
The GINA classification showed more severe degrees of asthma in the investigated group of 
smokers than in the group of non-smokers (Table 12), mostly in the case of moderate asthma 
(61% vs. 49%). Clinically, smokers with asthma have more severe asthma symptoms than 
asthmatic non-smokers54. 
During the past years, asthma control has become the most important part of the follow-up 
of asthmatic patients. The ACT has been recognized as a useful tool for asthma control and 
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validated in numerous countries, including Spain55 and Croatia56. For purposes of one of our 
previous studies, we recruited 90 consecutive patients with asthma (18-85 years of age, of 
which 50 women) that filled out the Croatian version of the ACT during their regular visits 
to the asthma outpatient clinic and during their follow-up visit after 3 months. In the case of 
the patients who made the second visit (after 3 months), significant correlation between the 
change in the ACT score and the change in the level of asthma control according to an 
asthma specialist was recorded (r2=0.437; P<0.001). In the current study, we found that the 
investigated ever-smokers had lower ACT scores in relation to the level of asthma control 
recorded in the investigated group of non-smokers (16 vs. 20), which means that asthma in 
connection with smoking entails a lower level of asthma control. Other authors also found 
that asthma in smokers was more difficult to control57.  
The exacerbation rate in the ever-smoking group was bigger than in the non-smoking group 
(31% vs. 26%). In the investigated group, 4/120 (3.3%) patients were hospitalized due to 
asthma exacerbation during the observation period. 11 (9.2%) of them were ever-
hospitalized for asthma exacerbation, some of them a few times. Two patients (1.7%) were 
treated in the Intensive Care Unit, but neither was mechanically ventilated. According to the 
literature data, smokers with asthma have more frequent and severe exacerbations of 
asthma than non-smokers with asthma and are therefore more likely to visit hospital 
emergency departments, more frequently need to be placed in intensive care units, and 
more frequently need to be put on invasive ventilation than non-smokers, which results in 
higher mortality due to asthma in the case of the same58. The number of investigated 
patients with asthma exacerbations was not high. This result confirms the known fact that 
after the inhaled steroid therapy had been introduced, the number of hospitalized patients 
with asthma exacerbation declined dramatically.  
The lung function analysis in both groups of patients with asthma, smokers and non-
smokers, even after being divided in subgroups, current and former smokers, did not show 
statistically significant differences (Table 13). Based on this particular study, no conclusion 
can be brought regarding the association of smoking and the FEV1 level, probably due to the 
fact that the sample included mainly young population, around 40 years of age.  
According to our results, the usual course of a respiratory allergy is that allergic rhinitis 
precedes the appearance of asthma. The duration of allergic rhinitis (AR) was significantly 
longer than the duration of asthma, p<0.001 (Table 2). Adults with allergic rhinitis who 
smoke are significantly more likely to develop asthma, which was confirmed by our results 
and other authors as well. The more a person smokes, the greater is the probability of 
developing more severe asthma types, thus making the asthma control more difficult59. 
Smoking influences the clinical presentation of allergic asthma and rhinitis, the severity of 
the disease and the success of the treatment. The success of the treatment is significantly 
better after the patient quits smoking, not just in the case of patients with asthma and 
allergic rhinitis, but also in lung cancer patients recording longer survival rates than those 
who continue to smoke. In asthmatic patients, smoking reduces the effect of drugs, such as 
inhaled corticosteroids60, which may lead to increased risk of hospitalization and intubation 
due to respiratory failure in the case of severe asthma exacerbations61. 
Due to the fact that most patients affected with allergic rhinitis are young, at the beginning 
of a career, this diagnosis has such a big impact on their life comparable to the impact on the 
patients with moderate asthma62. Allergic rhinitis and asthma phenotyping or, even better, 
endotyping, is important in terms of personalized medicine, the promising way to an 
individualized, tailored approach to each allergic patient.  
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9. Conclusion 
Smoking causes clinical differences in patients with allergic rhinitis and asthma phenotypes. 
Daily exposure to tobacco smoke among the investigated current non-smokers and current 
smokers proved to be a statistically significant predictor of allergic rhinitis and asthma. The 
ever-smoking patients have more severe asthma and more moderate to severe 
exacerbations, but experience less symptoms. Physicians should pay more attention to 
patients with allergic rhinitis and asthma phenotypes who smoke.  
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